Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Taps Regulus For microRNA Drug Development

This article was originally published in The Pink Sheet Daily

Executive Summary

Alnylam/Isis spinout Regulus nabs two high-profile partners for its microRNA platform by signing an agreement with AstraZeneca that includes a $28 million upfront payment and equity investment, and a separate deal with Biogen Idec.

You may also be interested in...



Flush With Cash And Partnered Up, Regulus Turns To Clinical Execution: An Interview With CEO Kleanthis Xanthopoulos

Regulus notched two partnerships and an IPO in 2012, putting it on firmer financial ground. Now, as it transitions to executing on its partnerships and pushing ahead with its internal programs, its task is to demonstrate the clinical utility of its miRNA compounds.

MicroRNA Momentum Builds, But Will Big Pharma Embrace It?

While interest in microRNA may not be moving at the speed that some investors (and, certainly, some smaller companies) may like, Big Pharma has taken notice of the little oligos and is watching the sector.

Deals Of The Week: AstraZeneca/Regulus, Biogen Idec/Regulus, Pfizer/AstraZeneca, Elan/Neotope

Next-wave patient-based research pioneer PatientsLikeMe struck an alliance with Merck to “evaluate the impact of psoriasis on patients and to inform a novel approach to improving outcomes.”

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS074514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel